Raccurt C P, Dumestre-Toulet V, Abraham E, Le Bras M, Brachet-Liermain A, Ripert C
Centre de Vaccinations Internationales Sante-Voyages, Controle Sanitaire aux Frontieres, Bordeaux, France.
Am J Trop Med Hyg. 1991 Sep;45(3):319-24. doi: 10.4269/ajtmh.1991.45.319.
Due to the spread of chloroquine-resistant strains of Plasmodium falciparum in French speaking parts of Africa, we have found it necessary to prescribe mefloquine for antimalaria prophylaxis to travelers to this area. Weekly doses of 125 or 250 mg have been recommended for short journeys. In spite of this regimen, 16 documented cases of falciparum malaria in travelers have been recorded in the Bordeaux hospital center since October, 1988. Fifteen of these patients were tourists returning from West African countries, and one was an Ivorian student who had been on vacation to his home country. Nine of these patients were evaluated and found to have high plasma mefloquine levels. This report strongly supports the existence of mefloquine-resistant falciparum malaria in West Africa, especially in Sierra Leone, Burkina Faso, and Cote d'Ivoire.
由于耐氯喹恶性疟原虫菌株在非洲法语区的传播，我们发现有必要为前往该地区的旅行者开甲氟喹用于疟疾预防。对于短途旅行，建议每周服用125或250毫克剂量。尽管采用了这种方案，但自1988年10月以来，波尔多医院中心已记录到16例旅行者患恶性疟的确诊病例。其中15名患者是从西非国家归来的游客，1名是回祖国度假的科特迪瓦学生。对其中9名患者进行评估后发现其血浆甲氟喹水平较高。本报告有力地支持了西非存在耐甲氟喹恶性疟，尤其是在塞拉利昂、布基纳法索和科特迪瓦。
